These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7986719

  • 81. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M.
    Circulation; 2011 Oct 04; 124(14):1573-9. PubMed ID: 21900088
    [Abstract] [Full Text] [Related]

  • 82. Concentrates containing factor IX could improve haemostasis under conditions of thrombocytopenia: studies in an in vitro model.
    Galán AM, Reverter JC, Pino M, Viñas M, Bozzo J, Hernández MR, Aznar-Salatti J, Ordinas A, Escolar G.
    Vox Sang; 2002 Apr 04; 82(3):113-8. PubMed ID: 11952983
    [Abstract] [Full Text] [Related]

  • 83.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 84. Development of large-scale fractionation methods. II. Isolation of a factor IX concentrate (prothrombin complex) for clinical use.
    Wickerhauser M, Sgouris JT.
    Vox Sang; 1972 Apr 04; 22(2):137-60. PubMed ID: 5013242
    [No Abstract] [Full Text] [Related]

  • 85.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 86.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 87.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 88. Thrombogenicity of prothrombin complex concentrates.
    Köhler M.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S13-7. PubMed ID: 10499904
    [Abstract] [Full Text] [Related]

  • 89.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 90.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 91. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III.
    Hoffman C, Hultin MB.
    Thromb Res; 1986 Jul 15; 43(2):143-51. PubMed ID: 3738857
    [Abstract] [Full Text] [Related]

  • 92. Removal of hepatitis B virus from a concentrate of coagulation factors II, VII, IX and X by hydrophobic interaction chromatography.
    Einarsson M, Kaplan L, Nordenfelt E, Miller E.
    J Virol Methods; 1981 Nov 15; 3(4):213-28. PubMed ID: 7328163
    [Abstract] [Full Text] [Related]

  • 93. Single-dose pharmacokinetics of factor IX evaluated by model-independent methods.
    Longo G, Cinotti S, Filimberti E, Giustarini G, Messori A, Morfini M, Ferrini PR.
    Eur J Haematol; 1987 Nov 15; 39(5):426-33. PubMed ID: 3691761
    [Abstract] [Full Text] [Related]

  • 94.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 95.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 96. Labeled factor IX kinetics in patients with hemophilia-B.
    Smith KJ, Thompson AR.
    Blood; 1981 Sep 15; 58(3):625-9. PubMed ID: 7259841
    [Abstract] [Full Text] [Related]

  • 97. Plasma thromboplastin component (PTC), a hitherto unrecognized blood coagulation factor; case report of PTC deficiency.
    WHITE SG, AGGELER PM, GLENDENING MB.
    Blood; 1953 Feb 15; 8(2):101-24. PubMed ID: 13018345
    [No Abstract] [Full Text] [Related]

  • 98. [Isolation of factor IX concentrate from cryosupernatant of donor's plasma].
    Fetisova LV, Viazova EP, Khametova RN, Shuvalova AL, Azhigirova MA, Lazarev VA, Zeĭnalov AM.
    Gematol Transfuziol; 1991 Jun 15; 36(6):34-6. PubMed ID: 1769497
    [Abstract] [Full Text] [Related]

  • 99.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 100.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.